Pseudomonas aeruginosa: Recent Advances in Vaccine Development

Pseudomonas aeruginosa is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, P. aeruginosa causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are...

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2022-07, Vol.10 (7), p.1100
Main Authors: Killough, Matthew, Rodgers, Aoife, Ingram, Rebecca
Format: Article
Language:English
Subjects:
Adaptation
Antibiotic resistance
Antibiotics
Antigens
Antimicrobial agents
Bacteria
Biofilms
Clinical trials
Cystic fibrosis
Disease
Drug resistance
Morbidity
Mortality
mucosal immunity
Nosocomial infections
Opportunist infection
Pathogenesis
Pathogens
Pneumonia
Pseudomonas aeruginosa
Review
Vaccination
Vaccine development
Vaccines
Ventilator-associated pneumonia
Ventilators
Virulence
Virulence factors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pseudomonas aeruginosa is an important opportunistic human pathogen. Using its arsenal of virulence factors and its intrinsic ability to adapt to new environments, P. aeruginosa causes a range of complicated acute and chronic infections in immunocompromised individuals. Of particular importance are burn wound infections, ventilator-associated pneumonia, and chronic infections in people with cystic fibrosis. Antibiotic resistance has rendered many of these infections challenging to treat and novel therapeutic strategies are limited. Multiple clinical studies using well-characterised virulence factors as vaccine antigens over the last 50 years have fallen short, resulting in no effective vaccination being available for clinical use. Nonetheless, progress has been made in preclinical research, namely, in the realms of antigen discovery, adjuvant use, and novel delivery systems. Herein, we briefly review the scope of P. aeruginosa clinical infections and its major important virulence factors.
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines10071100